Episode #127 High Truths on Drugs and Addiction with Dr. Brooks Gentry and Monoclonal Antibody Treatment For Methamphetamine Use DisorderEpisode #127 High Truths on Drugs and Addiction with Dr. Brooks Gentry and Monoclonal Antibody Treatment For Methamphetamine Use Disorder
High Truths on Drugs and Addiction
What are some upcoming innovations for methamphetamine use disorder? Learn from Dr. Brooks Gentry how monoclonal antibodies can be the new MAT for meth. Intervexion Therapeutics Outlast Study W. Brooks Gentry, MD Dr. Brooks Gentry is a Professor in the Department of Anesthesiology at the University of Arkansas for Medical Sciences (UAMS), where he has served as Vice-Chair for Research since 2002, and a Professor in the Department of Pharmacology and Toxicology. He is also Chief Medical Officer for InterveXion Therapeutics and Chief Medical Officer for Kuria Therapeutics. Among many leadership roles and service posts on campus, he was Chair of the UAMS Department of Anesthesiology from 2014-2018, and he chaired the UAMS Committee on Clinical Research from 2009 to 2013. Dr. Gentry is retired from clinical medicine but had clinical interests in ambulatory and trauma anesthesiology and practiced in all specialties except for liver transplant, cardiac and pediatric anesthesiology. He has also been active in teaching and advising medical students, residents and graduate students throughout his career. He has received 10 student-selected Red Sash awards for teaching. Since 1998, Dr. Gentry has partnered with Mike Owens, Ph.D., on widely recognized, National Institute on Drug Abuse (NIDA)-funded research into the development of therapies for substance use disorders. Dr. Gentry was principal investigator on the first human studies of a chimeric anti-methamphetamine monoclonal antibody medication and has continued to lead three other clinical trials of this medication. Dr. Gentry’s and Dr. Owens’ work also led to the formation of InterveXion Therapeutics LLC, a UAMS BioVentures company working to develop monoclonal antibody and vaccine medications, with Dr. Gentry serving as Chief Medical Officer. In his role as Chief Medical Officer of InterveXion, he has substantial input into the development and performance of the Phase 1 and 2 studies of IXT-m200, and into the interpretation of the results. He interacts the site PIs of the studies, and is involved in many safety and medical decisions regarding these studies. Dr. Gentry served as an Oral Examiner for the American Board of Anesthesiology and as Medical Editor for the American Society of Anesthesiologists Self-Education and Evaluation program, a major national continuing medical education program. He has been a reviewer for several publications including the Journal of Pharmacology and Experimental Therapeutics. He has authored or co-authored more than 50 scientific papers and two book chapters. Dr. Gentry received a B.A. with distinction in biology from Hendrix College in Conway, Arkansas, in 1984 and his medical degree from UAMS in 1988. He trained in anesthesiology at Northwestern University in Chicago, where he also served as Chief Resident and completed a fellowship in clinical pharmacology and pharmacokinetics before joining the UAMS faculty in 1994.
52:20•29 May 2023
Breaking New Ground: Monoclonal Antibodies for Meth Addiction
Episode Overview
- Dr. Brooks Gentry, a leading expert, shares insights into developing a monoclonal antibody treatment for methamphetamine use disorder.
- The podcast highlights the medical approach to substance use disorder, emphasizing the need for innovative treatments and compassion in addiction medicine.
- Challenges in drug development and the future of addiction medicine are discussed, providing valuable information for those interested in the field.
- The conversation delves into the long-term effects of methamphetamine, pregnancy and substance use disorder, and multidisciplinary treatment approaches, offering a comprehensive view of the topic.
- Stigma and compassion in addiction treatment are addressed, shedding light on the importance of understanding substance use disorder as a medical illness.
“We believe that this is a medical illness and not a social ill. The more we can do to develop new medications, the more we can help these folks.”
Imagine a world where methamphetamine addiction could be treated with the same precision as cancer. That's what Dr. Brooks Gentry is striving for in this eye-opening episode of 'High Truths on Drugs and Addiction'. Hosted by Dr. Roneet Lev, an emergency and addiction physician with years of frontline experience, this episode dives into Dr. Gentry's pioneering work on monoclonal antibody treatments for methamphetamine use disorder. Dr.
Gentry, a seasoned professor at the University of Arkansas for Medical Sciences, shares his journey from clinical anesthesiology to groundbreaking research in addiction medicine. He explains how monoclonal antibodies could offer a new way to manage meth addiction, potentially changing the lives of millions struggling with this powerful drug. You'll hear about the science behind these treatments, the hurdles in drug development, and the compassionate approach needed to understand addiction as a medical illness.
This episode is a must-listen for anyone curious about innovative solutions in addiction treatment or looking for hope in the battle against methamphetamine use.
Do you want to link to this podcast?
Get the buttons here!
More From This Show
The latest episodes from the same podcast.
Related Episodes
Similar episodes from other shows in the catalogue.